After the transition is complete, Caforio will continue as chair of Bristol Myers’ board of directors, although it is not typical for U.S-based drugmakers to permanently split the CEO and board chair roles. The company said his tenure as chair will be “for a transition period to be determined by the board.”
Taking Boerner’s place as chief commercial officer will be Adam Lenkowsky, currently Bristol Myers’ head of major markets. That transition is effective immediately with Boerner’s elevation to COO.
A medical doctor, Caforio assumed the CEO’s role from Lamberto Andreotti in 2015 after having worked in numerous roles across the company, including as chief commercial officer and COO.
His tenure as Bristol Myers chief was defined by the company’s development of the blood thinner Eliquis and the cancer immunotherapy Opdivo into blockbuster medicines, as well as a string of big-ticket acquisitions, most notably a $74 billion acquisition of Celgene. That deal brought in the fast-selling blood cancer treatment Revlimid, making Bristol Myers one of the largest oncology companies, as well as the cancer cell therapies Abecma and Breyanzi, which now figure more prominently in its plans.
Yet Bristol Myers also misstepped under Caforio, choosing a clinical development plan for Opdivo that backfired and allowed rival Merck & Co. to take a leading position in the market for cancer immunotherapies. A big bet on an experimental immunotherapy developed by biotechnology company Nektar Therapeutics also didn’t pan out. READ MORE
By Jonathan Gardner
Source: biopharmadive.com
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.
